Key result
Evinacumab reduced LDL cholesterol by a mean of 49% (absolute change of -157 mg/dL) at 4 weeks in adults with homozygous familial hypercholesterolemia.
Why the study?
Does evinacumab reduce LDL cholesterol in adults with homozygous familial hypercholesterolemia?
Does evinacumab reduce LDL cholesterol in adults with homozygous familial hypercholesterolemia?
Evinacumab substantially reduces LDL cholesterol in patients with homozygous familial hypercholesterolemia.
May lower LDL in refractory HoFH; leaves open efficacy, safety, and durability in larger trials.
Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.
No takes yet. Share an insight, caveat, or question.
Gaudet et al. (2017) studied this question. Evinacumab reduced LDL cholesterol by a mean of 49% (absolute change of -157 mg/dL) at 4 weeks in adults with homozygous familial hypercholesterolemia.